Dicyclomine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Dicyclomine: Antimuscarinic antispasmodic → cauda equina syndrome
One-Sentence Summary
Dicyclomine is an antimuscarinic antispasmodic that relaxes smooth muscle and is marketed in Canada. The TxGNN model predicts it may be effective for cauda equina syndrome, with a prediction score of 0.9966. However, no clinical trials and no publications were found in the data compiled for this report, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | cauda equina syndrome |
| TxGNN Prediction Score | 0.9966 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for dicyclomine are not available in the data compiled for this report. Dicyclomine is generally understood as an antimuscarinic/antispasmodic agent that relaxes smooth muscle.
Cauda equina syndrome often presents with bladder and bowel dysfunction. A theoretical link exists only for symptom management, such as bowel spasm or detrusor overactivity. This link is weak: anticholinergic activity could worsen urinary retention, which is a core feature of the condition.
Cauda equina syndrome is a surgical emergency caused by nerve root compression. No mechanism is established by which dicyclomine would treat the underlying cause. The high score is a computational prediction only and is not backed by clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02366088 | JAMP-DICYCLOMINE HCL | Not recorded | Not recorded |
| 02391619 | JAMP-DICYCLOMINE HCL | Not recorded | Not recorded |
| 00557102 | RIVA-DICYCLOMINE | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: 100 interactions were recorded. Most listed ones are of moderate severity, including:
- Other anticholinergic or antimuscarinic agents (e.g., aclidinium, hyoscyamine, amitriptyline, chlorpheniramine, acrivastine)
- Opioids (e.g., fentanyl, codeine, tramadol, alfentanil, dihydrocodeine)
- Others: botulinum toxin type A, ethanol, amantadine, galantamine, loperamide, acebutolol
- Minor: acetaminophen, hydrochlorothiazide
- Clinical concern for this prediction: Anticholinergic effects may cause or worsen urinary retention, which is already a key feature of cauda equina syndrome.
Please refer to the package insert for warnings and contraindications, as these were not available in the compiled data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or publications (evidence level L5). The possible mechanism is weak and may even be harmful, because antimuscarinic action can worsen urinary retention.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications
- Mechanism-of-action data for dicyclomine
- Any clinical or preclinical study that directly addresses cauda equina syndrome
- A clinical safety assessment of urinary retention risk in this population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.